Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Introduction The ongoing novel coronavirus disease 2019 (COVID-19) pandemic has provoked questions about treatment decisions in patients with hematologic malignancies. Of note, several anti-cancer agents have been shown to have preclinical activity against the SARS-CoV-2 virus, including ruxolitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Daniel I., Tremblay, Douglas, Thibaud, Santiago, Mascarenhas, John, Gabrilove, Janice L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
906.Outcomes Research-Malignant Conditions (Myeloid Disease)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330207/
http://dx.doi.org/10.1182/blood-2020-137005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330207/
http://dx.doi.org/10.1182/blood-2020-137005

Ejemplares similares